Formycon To Update on its Biosimilar Programs

 Formycon To Update on its Biosimilar Programs

Formycon Reports Initiation of P-I Trial for FYB202 (biosimilar, ustekinumab)

  • Formycon signs an agreement with Bioeq AG and manufacturing partner for resubmission of BLA for FYB201 project (biosimilar, ranibizumab). Bioeq AG is in talks with the US FDA for resubmission supporting manufacturing data in the H2’20
  • In Oct 2019, Formycon’s FYB202 (biosimilar, ustekinumab) has completed its P-I trial with its initiation of P-III trial in Q3’20. FYB202 is a co-developed product with Aristo Pharma and Formycon AG while Aristo holds 75.1% and Formycon AG 24.9% and Bioeq will sponsor the trial
  • FYB203 (biosimilar, aflibercept) has received approval for neovascular age-related macular degeneration and is expected for P-III trial in mid-20 while Klinge Biopharma GmbH acquires the marketing rights for FYB203 from Santo Holding. Formycon’s FYB206 is in preclinical phase and its IP is established with filling of patent application

Click here to read full press release/ article | Ref: Formycon | Image: Behnace

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post